Results 201 to 210 of about 160,936 (251)

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Recurarization in the Post-anesthesia Care Unit One Hour After Sugammadex Administration: A Case Report. [PDF]

Cureus
Felix F, Marques F, Tenreiro G, Torres J, Carneiro S.   +4 more
europepmc   +1 more source

Ethical reflections on end-of-life signs and symptoms in the intensive care setting: a place for neuromuscular blockers? [PDF]

Ann Intensive Care, 2014
Daubin C, Haddad L, Folscheid D, Boyer A, Chalumeau-Lemoine L, Guisset O, Hubert P, Pillot J, Robert R, Dreyfuss D.   +9 more
europepmc   +1 more source

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Navigating Anxiety Management in Myasthenia Gravis Crisis With Prolonged Corrected QT (QTc): A Case Report. [PDF]

Cureus
Burky G.
europepmc   +1 more source

Selective modulation of NaV channel gating counteracts aberrant hyperexcitability and rescues motor function and survival in a model of spinal muscular atrophy

British Journal of Pharmacology, EarlyView.
Background and Purpose Spinal muscular atrophy (SMA) is a motor neuron disease caused by SMN1 gene loss, leading to reduced survival motor neuron (SMN) protein and progressive motor neuron degeneration. Although SMN‐restoring therapies improve outcomes, residual disease burden and non‐curative efficacy underscore the need for complementary treatments ...
Fernanda C. Cardoso, Jessica A. I. Muller, Yougang Zhang, Jean Giacomotto   +3 more
wiley   +1 more source

The effect of static and dynamic core exercises on serve and spike speed in young volleyball players: a randomized controlled trial. [PDF]

BMC Sports Sci Med Rehabil
Gok B, Acar G.
europepmc   +1 more source

Inhibition of Ornithine Decarboxylase 1 Mitigates Denervation‐Induced Muscle Atrophy by Suppressing Proteolysis and Preserving Muscle Stem Cell Homeostasis

Cell Proliferation, EarlyView.
Polyamine metabolism is innervation responsive and involved in denervation‐induced muscle atrophy. Inhibition of polyamine metabolism attenuates muscle atrophy by restraining proteolysis and preserving MuSCs homeostasis. Denervation‐induced activation of FAP‐derived FGF7 drives premature MuSCs activation, while DFMO suppresses this paracrine cue to ...
Mingming Zhang, Feifan Chang, Siliang Ge, Fuming Cao, Pincong Fu, Haobo Zhang, Ming Chen, Yi Li, Peifu Tang, Pengbin Yin   +9 more
wiley   +1 more source

In-depth exploration of sugammadex and novel neuromuscular blockade antagonists: a narrative review. [PDF]

Front Pharmacol
Qi Y, Xu X, Wu X, Luo L, Jie Q, Qi Y.
europepmc   +1 more source